Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Sling Therapeutics, Inc. closes $123 million Series C financing led by Forbion to advance Phase 3 development of its oral small molecule IGF-1R inhibitor for thyroid eye disease.
Amount Raised
$123 Million
Round Type
Series C
Ann ArborHealth CareInvestors
Description
Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company, has closed a $123 million Series C financing. The financing was led by Forbion with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the continued clinical advancement of their therapy for thyroid eye disease.
Fundz sees it the moment Sling Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Sling Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.